February 19, 2026- Cepheid announced that it has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators under a new federal initiative designed to accelerate the development and deployment of rapid diagnostic technologies during public health emergencies. The award—issued under a multiple-award Indefinite Delivery-Indefinite Quantity (IDIQ) contract—reinforces Cepheid’s longstanding leadership in outbreak response and its commitment to bolstering the nation’s pandemic readiness.
Through this collaboration, CDC can provide Cepheid with early access to outbreak samples, genomic sequences, and critical reference materials. This access aims to help close development gaps during early pathogen emergence and accelerate the creation of next-generation diagnostic assays, ensuring that rapid, accurate testing can be deployed quickly when new threats arise.